Literature DB >> 22586053

Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.

Fengmei Wang1, Xiang Jing, Tao Wang, Ge Li, Tinghong Li, Qin Zhang, Yong Huang, Jun Li, Yijun Wang, Yingtang Gao, Tao Han, Zhi Du.   

Abstract

The diagnostic value of combining glypican-3 (GPC3) and CD34 staining for small nodules in liver biopsy specimens has not been evaluated. In this study, 201 thin-core biopsy specimens were assessed using GPC3 and CD34 immunochemical staining, including 33 cirrhotic regenerative nodules, 31 high-grade dysplastic nodules, 70 hepatocellular carcinomas (HCCs) with nodules 3 cm or smaller, and 67 HCCs with nodules larger than 3 cm. The results showed that the accuracy of GPC3 staining (90.3%) among liver nodules 3 cm or smaller was better than its use among all nodules (P = .045). Furthermore, the positive expression rate of costaining was significantly greater than that observed for GPC3 or CD34 single staining (P < .001 and P = .002, respectively). These data demonstrate that GPC3 staining is more accurate for the diagnosis of HCC on thin-core biopsy specimens in nodules 3 cm or smaller compared with its use in all nodules, while GPC3 and CD34 costaining has better diagnostic value than does single staining.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22586053     DOI: 10.1309/AJCP0KZZ5DSIGMNY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.

Authors:  Ying Liu; Dongping Zheng; Mingming Liu; Jiao Bai; Xi Zhou; Baolan Gong; Jieyu Lü; Yi Zhang; Hui Huang; Wenying Luo; Guangrong Huang
Journal:  Tumour Biol       Date:  2015-05-14

Review 2.  Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.

Authors:  Li-Li Han; Yi Lv; Hui Guo; Zhi-Ping Ruan; Ke-Jun Nan
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 3.  Histopathology of hepatocellular carcinoma.

Authors:  Manuel Schlageter; Luigi Maria Terracciano; Salvatore D'Angelo; Paolo Sorrentino
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 4.  Glypican-3 antibodies: a new therapeutic target for liver cancer.

Authors:  Mingqian Feng; Mitchell Ho
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

5.  Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.

Authors:  Issei Kawashima; Yuri Kawashima; Yasuo Matsuoka; Kiyotaka Fujise; Hideki Sakai; Mari Takahashi; Toshiaki Yoshikawa; Tetsuya Nakatsura; Takeshi Ishihara; Tadao Ohno
Journal:  Clin Case Rep       Date:  2015-04-17

6.  Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.

Authors:  Preeyanat Vongchan; Robert J Linhardt
Journal:  World J Hepatol       Date:  2017-03-08

7.  Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Azadeh Andisheh-Tadbir; Amir Saeed Goharian; Mohammad Ali Ranjbar
Journal:  J Dent (Shiraz)       Date:  2020-06

8.  Evaluation of Glypican-3 expression in benign and malignant salivary gland tumors.

Authors:  Azadeh Andisheh-Tadbir; Mohammad Javad Ashraf; Ali Gudarzi; Razieh Zare
Journal:  J Oral Biol Craniofac Res       Date:  2018-09-06

9.  Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.

Authors:  Yoshio Shimizu; Takafumi Tamura; Akira Kemmochi; Yohei Owada; Yusuke Ozawa; Katsuji Hisakura; Takashi Matsuzaka; Hitoshi Shimano; Noriyuki Nakano; Shingo Sakashita; Tatsuya Oda; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2020-10-05       Impact factor: 4.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.